ONCR Stock Overview
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients.
Notes are coming soon
Oncorus, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.43|
|52 Week High||US$3.26|
|52 Week Low||US$0.23|
|1 Month Change||53.54%|
|3 Month Change||-25.54%|
|1 Year Change||-85.81%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-97.33%|
Recent News & Updates
Oncorus GAAP EPS of -$0.74 misses by $0.02Aug 04
We're Not Very Worried About Oncorus' (NASDAQ:ONCR) Cash Burn RateOct 14
Oncorus: Shares Look Cheap As First Oncolytic Viral Therapy Enters ClinicJul 09
Oncorus (NASDAQ:ONCR) Is In A Good Position To Deliver On Growth PlansMay 05
What Kind Of Shareholders Own Oncorus, Inc. (NASDAQ:ONCR)?Feb 26
Oncorus: Buy On A Dip, Potential Already Priced In At Current LevelsFeb 02
Oncorus to build viral immunotherapy clinical manufacturing facility in U.S.Jan 04
We're Not Very Worried About Oncorus' (NASDAQ:ONCR) Cash Burn RateJan 04
Oncorus reports Q3 resultsNov 11
|ONCR||US Biotechs||US Market|
Return vs Industry: ONCR underperformed the US Biotechs industry which returned 3.9% over the past year.
Return vs Market: ONCR underperformed the US Market which returned -12.5% over the past year.
|ONCR Average Weekly Movement||18.8%|
|Biotechs Industry Average Movement||12.2%|
|Market Average Movement||6.8%|
|10% most volatile stocks in US Market||17.5%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: ONCR is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 19% a week.
Volatility Over Time: ONCR's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company’s lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus.
Oncorus, Inc. Fundamentals Summary
|ONCR fundamental statistics|
Is ONCR overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ONCR income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-2.94|
|Net Profit Margin||0.00%|
How did ONCR perform over the long term?See historical performance and comparison